BMJ 2002;324:1287-1288 ( 1 June )

Editorials

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Adequate analysis of the CLASS trial indicates that this may not be the case

The first 150 words of the full text of this article appear below.

Selective cyclo-oxygenase 2 (COX 2) inhibitors, including celecoxib (Celebrex) and rofecoxib (Vioxx), are hypothesised to have a lower risk of gastrointestinal complications than traditional non-steroidal anti-inflammatory drugs.¹ In September 2000 the celecoxib long term arthritis safety study, better known as CLASS, was published in JAMA.² This trial, widely cited and distributed, concluded that a COX 2 inhibitor was associated with a lower incidence of complications than traditional non-steroidal anti-inflammatory drugs. What was much less widely publicised were criticisms that contradicted this conclusion.

CLASS was reported as a three arm trial comparing celecoxib 800 mg/day with ibuprofen 2400 mg/day and diclofenac 150 mg/day in osteoarthritis or rheumatoid arthritis. Clinically relevant upper gastrointestinal ulcer complications (bleeding, perforation, or obstruction) and symptomatic ulcers during the first six months of treatment were described as the two main outcome measures, comparing incidence rates for celecoxib and a traditional non-steroidal anti-inflammatory drug (fig 1). It was concluded that, compared with . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: What does evidence from randomised trials show about celecoxib?

Jonathan L Underhill
BMJ 2005 331: 1474-1475. [Extract] [Full Text]

Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

Julia Hippisley-Cox, Carol Coupland, and Richard Logan
BMJ 2005 331: 1310-1316. [Abstract] [Full Text] [PDF]

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

Julia Hippisley-Cox and Carol Coupland
BMJ 2005 330: 1366. [Abstract] [Full Text] [PDF]

Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study

Julie Pildal, An-Wen Chan, Asbjørn Hróbjartsson, Elisabeth Forfang, Douglas G Altman, and Peter C Gøtzsche
BMJ 2005 330: 1049. [Abstract] [Full Text] [PDF]

Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis

Peter Jüni, Rebekka Sterchi, Paul Dieppe, Scott Metcalfe, Sean Dougherty, Wayne McNee, Jonathan J Deeks, Lesley A Smith, and Matthew D Bradley
BMJ 2003 326: 334. [Extract] [Full Text] [PDF]

Are selective COX 2 inhibitors superior to traditional NSAIDs?

Brian R Budenholzer, G Steven Geis, Muhammad Mamdani, David N Juurlink, Geoffrey M Anderson, Richard R Stover, Peter Jüni, Anne W S Rutjes, and Paul Dieppe
BMJ 2002 325: 161. [Extract] [Full Text] [PDF]

Tales of discovery, obfuscation, error, and improvement
BMJ 2002 324: 0. [Full Text] [PDF]

This article has been cited by other articles:

• Merry, A. F. (2008). Ethics, Industry, and Outcomes. SEMIN CARDIOTHORAC VASC ANESTH 12: 7-11 [Abstract]  
• Pyrko, P., Kardosh, A., Liu, Y.-T., Soriano, N., Xiong, W., Chow, R. H., Uddin, J., Petasis, N. A., Mircheff, A. K., Farley, R. A., Louie, S. G., Chen, T. C., Schonthal, A. H. (2007). Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Molecular Cancer Therapeutics 6: 1262-1275 [Abstract] [Full text]  
• Ong, C.K.S., Lirk, P., Tan, C.H., Seymour, R.A. (2007). An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs. Clin Med Res 5: 19-34 [Abstract] [Full text]  
• Gibson, M., Santa, J. (2006). The Drug Effectiveness Review Project: An Important Step Forward. Health Aff (Millwood) 25: W272-W275 [Abstract] [Full text]  
• Rahme, E., Toubouti, Y., Hunsche, E. (2006). Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada. Rheumatology (Oxford) 45: 903-910 [Abstract] [Full text]  
• Dieppe, P. (2006). Complicity theory: an explanation for the ;coxib problem'?. JRSM 99: 273-274 [Full text]  
• Weatherall, M., Aldington, S., Caldwell, B., Beasley, R. (2006). Inconsistencies in cardiovascular data from COX-2 inhibitor trials--is it a class effect?. JRSM 99: 275-276 [Full text]  
• Wallace, J. L. (2006). Commonality of Defensive Roles of COX-2 in the Lung and Gut. Am. J. Pathol. 168: 1060-1063 [Full text]  
• Caldwell, B., Aldington, S., Weatherall, M., Shirtcliffe, P., Beasley, R. (2006). Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.. JRSM 99: 132-140 [Abstract] [Full text]  
• Underhill, J. L (2005). Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: What does evidence from randomised trials show about celecoxib?. BMJ 331: 1474-1475 [Full text]  
• Hippisley-Cox, J., Coupland, C., Logan, R. (2005). Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 331: 1310-1316 [Abstract] [Full text]  
• SPINK, M., BAHN, S., GLICKMAN, R. (2005). Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management: Benefits and risks. Journal of the American Dental Association 136: 1439-1448 [Abstract] [Full text]  
• Pratico, D., Dogne, J.-M. (2005). Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine. Circulation 112: 1073-1079 [Full text]  
• Hippisley-Cox, J., Coupland, C. (2005). Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330: 1366- [Abstract] [Full text]  
• Pildal, J., Chan, A.-W., Hrobjartsson, A., Forfang, E., Altman, D. G, Gotzsche, P. C (2005). Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ 330: 1049- [Abstract] [Full text]  
• Schror, K., Mehta, P., Mehta, J. L. (2005). Cardiovascular Risk of Selective Cyclooxygenase-2 Inhibitors. J CARDIOVASC PHARMACOL THER 10: 95-101 [Abstract]  
• (2005). Taking stock of coxibs. DTB 43: 1-6 [Abstract] [Full text]  
• Zara, C., Torralba, M., Sotoca, J. M, Prat, A., Faixedas, M.-T., Gilabert, A. (2005). The Impact of New Drug Introduction on Drug Expenditure in Primary Health Care in Catalunya, Spain. The Annals of Pharmacotherapy 39: 177-182 [Abstract] [Full text]  
• Bjordal, J. M., Ljunggren, A. E., Klovning, A., Slordal, L. (2004). Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 329: 1317- [Abstract] [Full text]  
• Misra, U K, Jose, M, Kalita, J (2004). Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial. Postgrad. Med. J. 80: 720-723 [Abstract] [Full text]  
• Tannenbaum, H, Berenbaum, F, Reginster, J-Y, Zacher, J, Robinson, J, Poor, G, Bliddal, H, Uebelhart, D, Adami, S, Navarro, F, Lee, A, Moore, A, Gimona, A (2004). Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis 63: 1419-1426 [Abstract] [Full text]  
• Dieppe, P. A, Ebrahim, S., Martin, R. M, Juni, P. (2004). Lessons from the withdrawal of rofecoxib. BMJ 329: 867-868 [Full text]  
• Jacobsen, R. B, Phillips, B. B. (2004). Reducing Clinically Significant Gastrointestinal Toxicity Associated with Nonsteroidal Antiinflammatory Drugs. The Annals of Pharmacotherapy 38: 1469-1481 [Abstract] [Full text]  
• WARNER, T. D., MITCHELL, J. A. (2004). Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 18: 790-804 [Abstract] [Full text]  
• Hall, E J, Sykes, N P (2004). Analgesia for patients with advanced disease: 2. Postgrad. Med. J. 80: 190-195 [Abstract] [Full text]  
• Brandt, K D (2004). Non-surgical treatment of osteoarthritis: a half century of "advances". Ann Rheum Dis 63: 117-122 [Full text]  
• Gibson, L. (2004). Drug company sues Spanish bulletin over fraud claim. BMJ 328: 188-188 [Full text]  
• Wright, J. M. (2003). Why don't we initiate more large simple randomized controlled trials?. CMAJ 169: 1170-1171 [Full text]  
• Layton, D., Hughes, K., Harris, S., Shakir, S. A. W. (2003). Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 42: 1332-1341 [Abstract] [Full text]  
• Lisse, J. R., Perlman, M., Johansson, G., Shoemaker, J. R., Schechtman, J., Skalky, C. S., Dixon, M. E., Polis, A. B., Mollen, A. J., Geba, G. P., for the ADVANTAGE Study Group*, (2003). Gastrointestinal Tolerability and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthritis: A Randomized, Controlled Trial. ANN INTERN MED 139: 539-546 [Abstract] [Full text]  
• Geis, G S. (2003). CLASS clarification: reaffirms the medical importance of the analyses and results. BMJ 327: E143-144 [Full text]  
• Whittle, B J R (2003). New dogmas or old?. Gut 52: 1379-1381 [Abstract] [Full text]  
• Morreim, E. H. (2003). A Dose of Our Own Medicine: Alternative Medicine, Conventional Medicine, and the Standards of Science. J Law Med Ethics 31: 222-235  
• Gajraj, N. M. (2003). Cyclooxygenase-2 Inhibitors. Anesth. Analg. 96: 1720-1738 [Full text]  
• Figueras, A., Laporte, J.-R. (2003). Failures of the therapeutic chain as a cause of drug ineffectiveness. BMJ 326: 895-896 [Full text]  
• Hawkey, C J, Langman, M J S (2003). Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 52: 600-608 [Abstract] [Full text]  
• Juni, P., Sterchi, R., Dieppe, P., Metcalfe, S., Dougherty, S., McNee, W., Deeks, J. J, Smith, L. A, Bradley, M. D (2003). Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. BMJ 326: 334-334 [Full text]  
• Juni, P., Dieppe, P., Egger, M., Solomon, D., Avorn, J., Glynn, R. J., Rahme, E., Pilote, L., LeLorier, J., Watson, D. J., Rhodes, T., Cai, B., Guess, H. A. (2002). Risk of Myocardial Infarction Associated With Selective COX-2 Inhibitors: Questions Remain. Arch Intern Med 162: 2639-2642 [Full text]  
• Wright, J. M. (2002). The double-edged sword of COX-2 selective NSAIDs. CMAJ 167: 1131-1137 [Abstract] [Full text]  
• Grove, M. L (2002). US Food and Drug Administration gets it right. BMJ 325: 776-776 [Full text]  
• Yeager, A. L. (2002). JADA INDUSTRY ADVISORY BOARD. Journal of the American Dental Association 133: 1319-1320 [Full text]  
• Jones, R. (2002). Efficacy and safety of COX 2 inhibitors. BMJ 325: 607-608 [Full text]  
• Deeks, J. J, Smith, L. A, Bradley, M. D (2002). Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 325: 619-619 [Abstract] [Full text]  
• Mamdani, M., Rochon, P. A, Juurlink, D. N, Kopp, A., Anderson, G. M, Naglie, G., Austin, P. C, Laupacis, A. (2002). Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 325: 624-624 [Abstract] [Full text]  
• (2002). Robin Goodfellow. Rheumatology (Oxford) 41: 959-959 [Full text]  
• Budenholzer, B. R, Geis, G S., Mamdani, M., Juurlink, D. N, Anderson, G. M, Stover, R. R, Juni, P., Rutjes, A. W S, Dieppe, P. (2002). Are selective COX 2 inhibitors superior to traditional NSAIDs?. BMJ 325: 161-161 [Full text]  
• Skelly, M M, Hawkey, C J (2002). Potential alternatives to COX 2 inhibitors. BMJ 324: 1289-1290 [Full text]  

Rapid Responses:

Read all Rapid Responses

Rofecoxib did not provide unequivocal benefit over traditional non-steroidal agents

Brian R Budenholzer
bmj.com, 1 Jun 2002 [Full text]

Safety of selective COX-2 inhibitors

Magi Farré, et al.
bmj.com, 2 Jun 2002 [Full text]

Marketing by manipulated and falsified data, a rapidly growing drug business

Jutta M. Halbekath, et al.
bmj.com, 7 Jun 2002 [Full text]

Are COX 2 inhibitors inferior to NSAIDs?

James M Wright
bmj.com, 8 Jun 2002 [Full text]

Both CLASS and VIGOR support the COX-2 hypothesis

Richard R. Stover
bmj.com, 11 Jun 2002 [Full text]

Misleading promotion for celecoxib

Agnes I Vitry, et al.
bmj.com, 12 Jun 2002 [Full text]

COX-2 Inhibitors: What Do We Know About Them?

Muhammad Mamdani, et al.
bmj.com, 14 Jun 2002 [Full text]

Pharmacia Addresses June 1 Editorial Regarding CLASS Study

G. Steven Geis
bmj.com, 25 Jun 2002 [Full text]

Authors' response: fueling the debate

Peter Juni, et al.
bmj.com, 9 Jul 2002 [Full text]

Pharmacia addresses June 1 editorial regarding CLASS study: authors' response

Peter Juni, et al.
bmj.com, 12 Jul 2002 [Full text]

COX-2 inhibitors - expensive and unsafe

Cristian C. Baicus, et al.
bmj.com, 9 Aug 2002 [Full text]

VIGOR authors comments on responses to Juni's editorial

Claire Bombardier, et al.
bmj.com, 23 Aug 2002 [Full text]